Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study.

Standard

Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study. / Erbersdobler, Andreas; Isbarn, Hendrik; Steiner, Isabel; Schlomm, Thorsten; Chun, Felix; Mirlacher, Martina; Sauter, Guido.

in: UROLOGY, 2009.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

APA

Vancouver

Erbersdobler A, Isbarn H, Steiner I, Schlomm T, Chun F, Mirlacher M et al. Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study. UROLOGY. 2009.

Bibtex

@article{fd7247660791433f915abd23024cea58,
title = "Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study.",
abstract = "OBJECTIVES: To evaluate the prognostic potential of prostate-specific antigen (PSA) expression in tumor specimens in a large cohort of prostate cancers treated by prostatectomy. Although serum PSA measurement has been established as a diagnostic and prognostic tool in prostate cancer, no larger studies have been done of the prognostic potential of this parameter. METHODS: We used a tissue microarray containing samples of 3261 prostatectomy specimens. PSA expression was scored after immunohistochemical staining on a scale from 0 (absent) to 3 (strong) by an investigator unaware of all other variables. The results were correlated with the pre- and postoperative clinical and pathologic parameters and follow-up data. RESULTS: Of 2556 eligible tumors, PSA expression was strong in 48.0%, moderate in 36.7%, weak in 12.2%, and absent in 3.1%. The loss of PSA expression correlated significantly with a greater Gleason score, the presence of extraprostatic extension, and a peripheral zone prostate cancer location. It was also significantly associated with PSA recurrence after prostatectomy on univariate analysis but not on multivariate analysis containing the pathologic parameters of the prostatectomy specimens. In the subsets of patients with a preoperative PSA value",
author = "Andreas Erbersdobler and Hendrik Isbarn and Isabel Steiner and Thorsten Schlomm and Felix Chun and Martina Mirlacher and Guido Sauter",
year = "2009",
language = "Deutsch",
journal = "UROLOGY",
issn = "0090-4295",
publisher = "Elsevier Inc.",

}

RIS

TY - JOUR

T1 - Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study.

AU - Erbersdobler, Andreas

AU - Isbarn, Hendrik

AU - Steiner, Isabel

AU - Schlomm, Thorsten

AU - Chun, Felix

AU - Mirlacher, Martina

AU - Sauter, Guido

PY - 2009

Y1 - 2009

N2 - OBJECTIVES: To evaluate the prognostic potential of prostate-specific antigen (PSA) expression in tumor specimens in a large cohort of prostate cancers treated by prostatectomy. Although serum PSA measurement has been established as a diagnostic and prognostic tool in prostate cancer, no larger studies have been done of the prognostic potential of this parameter. METHODS: We used a tissue microarray containing samples of 3261 prostatectomy specimens. PSA expression was scored after immunohistochemical staining on a scale from 0 (absent) to 3 (strong) by an investigator unaware of all other variables. The results were correlated with the pre- and postoperative clinical and pathologic parameters and follow-up data. RESULTS: Of 2556 eligible tumors, PSA expression was strong in 48.0%, moderate in 36.7%, weak in 12.2%, and absent in 3.1%. The loss of PSA expression correlated significantly with a greater Gleason score, the presence of extraprostatic extension, and a peripheral zone prostate cancer location. It was also significantly associated with PSA recurrence after prostatectomy on univariate analysis but not on multivariate analysis containing the pathologic parameters of the prostatectomy specimens. In the subsets of patients with a preoperative PSA value

AB - OBJECTIVES: To evaluate the prognostic potential of prostate-specific antigen (PSA) expression in tumor specimens in a large cohort of prostate cancers treated by prostatectomy. Although serum PSA measurement has been established as a diagnostic and prognostic tool in prostate cancer, no larger studies have been done of the prognostic potential of this parameter. METHODS: We used a tissue microarray containing samples of 3261 prostatectomy specimens. PSA expression was scored after immunohistochemical staining on a scale from 0 (absent) to 3 (strong) by an investigator unaware of all other variables. The results were correlated with the pre- and postoperative clinical and pathologic parameters and follow-up data. RESULTS: Of 2556 eligible tumors, PSA expression was strong in 48.0%, moderate in 36.7%, weak in 12.2%, and absent in 3.1%. The loss of PSA expression correlated significantly with a greater Gleason score, the presence of extraprostatic extension, and a peripheral zone prostate cancer location. It was also significantly associated with PSA recurrence after prostatectomy on univariate analysis but not on multivariate analysis containing the pathologic parameters of the prostatectomy specimens. In the subsets of patients with a preoperative PSA value

M3 - SCORING: Zeitschriftenaufsatz

JO - UROLOGY

JF - UROLOGY

SN - 0090-4295

ER -